A stem cell transplant added to Rituxan did not improve survival for MRD-negative MCL patients in their first remission ...

Researchers at the meeting reported on long-term activity of commercialized gene therapies and preliminary data on ...

At ASH's annual meeting, a study showed the potential for this method to inform the next treatment after patients relapse on BCMA- or GPRC5D-targeted therapy.

The new Future Medicines Institute, based at Queen's University Belfast, is backed by government and industry.

The study is designed to evaluate the safety, tolerability, and preliminary efficacy of ATX-559 in certain biomarker-selected cancer patients.

Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.

The data suggest that multiple myeloma patients on Janssen's CAR T-cell therapy lived longer than on BMS's but experienced ...

Researchers founded Rarity PBC as a public benefit corporation that will license the IP and develop operations to potentially ...

The variant, present in the NFKB1 gene and common in the Aymara community, could help guide treatment decisions, researchers ...

In particular, patients who had fewer than 10 annual vaso-occlusive events before the gene therapy were more likely to have ...

Lymphoma patients better tolerated the CAR T-cell therapy manufactured on site at the Sheba Medical Center than they did the ...

In the Phase II ADVL1823 study, researchers evaluated Vitrakvi in children with newly diagnosed IFS and other solid tumors with NTRK fusions.